Why CRBP rose 21.0% on Sep 14 2026: positive phase 1b data

THE DAY ON THE LIST · 2 EVENTS

1. 04:08 ET
   UNEXPLAINED MOVE · PRE-MARKET

   $9.80 · ▲ 18.9% ON THE DAY · 44.3× 5M RVOL · RANK #4

   No verdict was committed for this event.

   THE ROW AND SESSION LEVELS AT 04:08 ET

   LAST9.80

   DAY▲ 18.9%

   5 MIN▲ 2.51%

   5M RVOL44.3×

   5M $VOL$170K

   FLOAT*18.7M

   RANK#4

   SESSIONPRE-MARKET

   VWAP9.87

   HOD10.19

   LOD7.95

   OR HIGH—

   OR LOW—

   PREV CLOSE8.24

   PM HIGH10.19

   PM LOW9.55

   GAP▲ 1.70%

   * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

   — MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO

2. 07:31 ET
   MOVER · PRE-MARKET

   $9.97 · ▲ 21.0% ON THE DAY · 984× 5M RVOL · RANK #2

   ✓JUSTIFIEDCONFIDENCE4/5

   Corbus reported positive, statistically significant Phase 1b topline data for its oral obesity candidate CRB-913, showing meaningful dose-dependent weight loss versus placebo in a 254-patient trial. The stock is up 18% pre-market on very heavy volume, consistent with a clinically de-risking readout in the hot obesity drug space.

   WHYAn 18% move on positive, statistically significant Phase 1b efficacy data in a small-float obesity biotech is proportionate given how binary and closely watched such readouts are.

   ANALYZED 07:30 ET · <1 MIN AGO · ANTHROPIC/CLAUDE-SONNET-5

   THE ROW AND SESSION LEVELS AT 07:31 ET

   LAST9.97

   DAY▲ 21.0%

   5 MIN▲ 8.71%

   5M RVOL984×

   5M $VOL$2.8M

   FLOAT*18.7M

   RANK#2

   SESSIONPRE-MARKET

   VWAP9.04

   HOD10.19

   LOD5.57

   OR HIGH—

   OR LOW—

   PREV CLOSE8.24

   PM HIGH10.19

   PM LOW5.57

   GAP▲ 1.70%

   * FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE

   — MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO

NO VERDICT MEANS THE MODEL HAD NOT REACHED THE NAME BEFORE THE EVENT WAS FINALIZED, OR ITS ANSWER HEDGED AND WAS WITHHELD. NOTHING WAS FILLED IN AFTERWARDS.